OK432 (Picibanil) in the Treatment of Lymphatic Malformations
Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
Standard of care for Lymphatic Malformations has been surgical excision. We have been using
OK432/Picibanil (generously supplied by Chugai Pharmaceuticals in Japan) since 1992 with
great success for macrocystic disease.
The objective of the study was to provide OK-432 immunotherapy to subjects with macrocystic
or mixed (> 50% macrocystic) lymphatic malformations (LMs) and investigate the efficacy and
safety of OK 432 as a treatment option in subjects with LMs.